To determine its activity, the effect of the newly synthesized compound was tested on estrogen-receptor-positive (ER+) breast cancer, which is characterized by aromatase overexpression on MCF-7 cells, as well as on the breast-cancer-cell-line-resistant LTED. The gene discussed is CYP19A1; the disease is breast cancer.